Stryker introduces InSpace in India, first biodegradable balloon implant for shoulder surgery

New Delhi: Stryker has announced the launch of InSpace, the first biodegradable balloon implant designed for the arthroscopic treatment of massive irreparable rotator cuff tears (MIRCTs) in India. This innovative product marks a significant advancement in the treatment of MIRCTs, one of the most common causes of shoulder dysfunction, offering a new option for surgeons to enhance patient care.

The InSpace balloon implant represents a breakthrough in shoulder surgery by restoring the subacromial space without the need for sutures or fixation devices. It has been shown to improve shoulder motion and function, providing a less invasive surgical solution compared to traditional methods.

Aman Rishi, Vice President and General Manager for Stryker in India, stated, “InSpace is a groundbreaking, first-of-its-kind technology, offering a new, minimally invasive surgical option for surgeons, addressing their unmet needs in MIRCT and potentially providing early functional recovery and pain relief for patients. We are committed to the advancement of shoulder arthroscopy and leading the way in the shoulder continuum of care.”

InSpace has a long and successful clinical history spanning over 14 years, with 35 peer-reviewed clinical articles and 41,000 balloons implanted worldwide. Some of the clinically proven advantages of InSpace include its less invasive nature, offering a streamlined surgical solution for MIRCTs compared to other options that require fixation devices or grafts. This makes the overall procedure less invasive.

Patients experience early and clinically meaningful improvements in shoulder motion and function, with an increase in range of motion compared to those who undergo partial repair surgery. Clinical studies have demonstrated comparable long-term safety and effectiveness results out to two years when compared to partial repair surgeries. Furthermore, patients, particularly those aged 65 and over, have shown a high likelihood of clinical success, with over 87% achieving positive outcomes at two years post-surgery.